KZA 3.03% 64.0¢ kazia therapeutics limited


  1. 22,691 Posts.
    At the moment, my prime focus is on NRT.

    Phase II trials started on Wednesday in the RNS Hospital, Sydney. These to be followed by others in the US.

    These involve intravenous injection of Phenoxidiol in a range of patients and covering Leukemias and some other diseases. These trials are susposed to finish at the end of Dec., although the results would be well known before the term is up, I think.

    This to be followed by a regime of Phenoxodiol (Pheno) and Cisplatin Trials till the end of June, 2003. It is these, I am interested in.

    Investors need to be aware that this has the potential to become a "biggie" as NRT also has a range of other drugs under development and all have litle or no side effects. This is one reason why the trials can be shortened and NRT is expecting the fullest co-operation from the FDA in the US.

    The drug NV07A has finished its trials and is set to go for discussions with Pharma companies.

    All I can tell you is that this is not only the most interested stock I have come across- one learns something about drugs- but it has the potential of having a much higher share value than most Australian stocks.

    It therefore ought to be treated with the respect it deserves.


watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Mkt cap ! $46.18M
Open High Low Value Volume
65.0¢ 66.0¢ 64.0¢ $29.92K 45.73K

Buyers (Bids)

No. Vol. Price($)
1 7693 64.0¢

Sellers (Offers)

Price($) Vol. No.
66.0¢ 18000 2
View Market Depth
Last trade - 14.29pm 10/12/2019 (20 minute delay) ?
-0.020 ( 1.54 %)
Open High Low Volume
66.0¢ 66.0¢ 64.0¢ 6933
Last updated 14.26pm 10/12/2019 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.